{
    "id": "correct_foundationPlace_00125_2",
    "rank": 87,
    "data": {
        "url": "https://www.crohnscolitisfoundation.org/clinical-trials-community/featured-research/clinical-trials/a-54-week-treatment-uc",
        "read_more_link": "",
        "language": "en",
        "title": "A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled (Entyvio), Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of A Study Drug in Par",
        "top_image": "https://www.crohnscolitisfoundation.org/sites/default/files/2020-07/twitter-card.png",
        "meta_img": "https://www.crohnscolitisfoundation.org/sites/default/files/2020-07/twitter-card.png",
        "images": [
            "https://www.crohnscolitisfoundation.org/sites/default/files/legacy/assets/images/allergan.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            "CCFA",
            "Crohn’s",
            "Crohn’s & Colitis"
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "Full Study Title: A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled (Entyvio), Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of A Study Drug in Participants with Moderately to Severely Active Ulcerative Colitis [Expedition] The primary objective of this study is to evaluate the efficacy and safety of a study drug versus placebo in patients with moderately to severely active Ulcerative Colitis.",
        "meta_lang": "en",
        "meta_favicon": "/sites/default/files/logo.png",
        "meta_site_name": "Crohn's & Colitis Foundation",
        "canonical_link": "https://www.crohnscolitisfoundation.org/clinical-trials-community/featured-research/clinical-trials/a-54-week-treatment-uc",
        "text": "Published: 01/25/2019\n\nGeneral Information:\n\nStudy Objective\n\nFull Study Title: A 54-Week Treatment, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Active-Controlled (Entyvio), Parallel-Group Phase 2 Study to Assess the Efficacy and Safety of A Study Drug in Participants with Moderately to Severely Active Ulcerative Colitis [Expedition]\n\nThe primary objective of this study is to evaluate the efficacy and safety of a study drug versus placebo in patients with moderately to severely active Ulcerative Colitis.\n\nPhase of study\n\nPhase 2\n\nRETURN TO TOP\n\nEligibility:\n\nAge\n\nAdult (18+)\n\nGender\n\nFemale\n\nMale\n\nDisease Type\n\nulcerative-colitis\n\nSeverity\n\nModerate\n\nSevere\n\nEligibility Criteria\n\nInclusion criteria:\n\nDiagnosis of Ulcerative Colitis (UC) for at least 3 months\n\nInadequate response or intolerance to conventional therapy for the treatment of UC\n\nEvidence of active UC based on the modified Mayo score\n\nNo known history of active TB (certain conditions withstanding)\n\nAgree to practice abstinence or adhere to specific birth control requirements\n\nExclusion criteria:\n\nParticipant has UC limited to the rectum\n\nHistory of fulminant colitis, a diagnosis of Crohn's disease or indeterminate colitis\n\nPrevious intolerance or non-response to Entyvio (vedolizumab)\n\nParticipants receiving exclusionary treatment within specified time periods\n\nHistory of cancer, except for basal cell carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix\n\nClinically significant infections\n\nClinically significant cardiovascular conditions\n\nCeliac disease\n\nBile acid malabsorption\n\nHistory of surgery for UC\n\nBreast-feeding or planning to become pregnant\n\nClinically significant kidney disease\n\nRETURN TO TOP\n\nStudy Details:\n\nStudy Description\n\nPatients will be randomly assigned to 1 of 5 study groups: three groups of active investigational study intervention at differing doses, one group of the active comparator Entyvio (Vedolizumab), and one group of placebo.\n\nThe study duration will consist of a 4-week screening period, a 54-week treatment period and an 18-week safety follow-up period.\n\nThe total study period will last up to 72 weeks.\n\nThe study doctor and study staff will not know if a participant is receiving study drug, Entyvio (vedolizumab) or placebo.\n\nPatients will have an 80% chance of getting an active drug.\n\nDescription of Treatment or Intervention (Mechanism of Action)\n\nThe investigational study intervention is believed to reduce inflammation in the colon and could possibly decrease the signs and symptoms of ulcerative colitis.\n\nThe investigational study intervention will be given to patients who have failed prior treatment, have had good response or have never had treatment with a biologic to see how well the drug works in different UC populations as compared to the active comparator.\n\nPatient Participation Requirements\n\nPatients will have a total of 19 study visits over the 72-week period.\n\nAfter screening, study intervention will be given through a needle in a vein (intravenously) for the first three visits.\n\nAt all other study visits, the study intervention will be given both intravenously and as an injection under your skin (subcutaneous) every four weeks.\n\nPatients will also be asked to complete an electronic diary to record their general health information and UC symptoms from screening until you exit the study.\n\nDiaries will be completed at specific intervals from screening until you exit the study.\n\nAt scheduled clinic visits, patients will also fill out questionnaires.\n\nColonoscopy will be performed at screening and two additional flexible sigmoidosopies will be performed thereafter.\n\nBlood and stool samples will also be taken at screening and at specific times during the study.\n\nPossible Risks & Side Effects\n\nThe study doctor will review all the possible risks and side effects of the experimental study intervention and active control at screening.\n\nRETURN TO TOP"
    }
}